Resistant Hypertension
Cardiovascular·MeSH: Cushing Syndrome
Prevalence
47000.0 / 100K
Incidence
3000.0 / 100K/yr
2 drugs in development·2 companies·3 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| cin-107 | CinCor Pharma, Inc. (CINC) |
Preclinical(1)
| Drug | Company |
|---|---|
| pb6440 | PhaseBio Pharmaceuticals Inc (PHAS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Resistant Hypertension?
BioSniper tracks 2 drugs in development for Resistant Hypertension across 2 companies.
How many clinical trials target Resistant Hypertension?
There are 3 clinical trials targeting Resistant Hypertension tracked by BioSniper.
What is the prevalence of Resistant Hypertension?
The estimated prevalence of Resistant Hypertension is approximately 47000.0 per 100,000 population.
Deep-dive into Resistant Hypertension
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis